RxDoctor Payments Data

Tamara Bockow Kaplan

Neurology · Boston, MANPI 1235491903

Payments from drug & device makers

$139,299in general payments, 2019–2025

Across 107 payments — averaging $1301.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$32K
  • Biogen$28K
  • Genentech USA, Inc.$26K
  • Sanofi$20K
  • Novartis$17K
  • Bristol Myers Squibb$9K
  • plus $8K from 4 others

What the payments were for

  • Consulting fees$112,31481%
  • Speaking & faculty fees$18,77813%
  • Travel & lodging$4,6983%
  • Food & beverage$3,4472%
  • Education$630%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.20$32,272
Biogen19$28,227
Genentech USA, Inc.22$26,324
Sanofi15$19,581
Novartis11$16,600
Bristol Myers Squibb10$8,756
TG Therapeutics, Inc.2$4,050
AstraZeneca5$3,247
Genentech, Inc.1$190
AbbVie2$53

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$139,299 in reported general payments places this provider in the 85th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$14,219
Medicare patients
80
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab30$302,418
Teriflunomide73$193,410
TecfideraDimethyl Fumarate11$101,211
MyrbetriqMirabegron30$15,753
Mirabegron ErMirabegron24$7,957
Modafinil34$5,824
Carbamazepine21$2,034
Trospium Chloride ErTrospium Chloride12$1,672
Baclofen45$1,161
Dalfampridine ErDalfampridine17$1,083
Gabapentin57$888
Lidocaine Hcl ViscousLidocaine Hcl28$708
Pregabalin13$594
Cyclobenzaprine Hcl16$183
Duloxetine Hcl11$161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$28,227$101,21111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 761 neurology providers in Massachusetts.

Other neurology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →